Vancouver, British Columbia, June 14, 2018 (GLOBE NEWSWIRE) -- EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: AXHLF) (the “Company”) announces that it has signed the Definitive Agreement with Cantech Molecular Research Inc. (“Cantech”).

“On the heels of our Letter of Intent with Cantech, we are pleased that EVITRADE has reached final terms on the Definitive Agreement” said CK Cheung, CEO of Evitrade.  “We are thrilled to have the world-class talents of Malcolm Lamont and his associates of Cantech on board with us.  Malcolm’s history and cutting-edge research into systems within plant science and genetics with large international plant seed supply and breeding firms will help put Evitrade at the top of the industry for the creation of superior breeding protocols and bench-marks in plant genetics.”

Among the many progressive capabilities EVA will gain with the Cantech acquisition is the ability to produce true homozygotic plants with a highly select and consistent set of traits. These can be used for a multitude of purposes such as: Plants with tailored CBD/THC combinations for a given illness but more importantly our plants will allow repeatability and consistency for the marketplace.

As Canada turns to enact legislation to legalize adult-use and improve laws for medical cannabis use, the possibilities for this technology are abundant.

Management continues to strive to seek optimal business and commercialization strategies for the Company; This, with the continued relationship with Haywood Securities as financial advisor, has the Company planning forward for a bright future.

C.K. Cheung, CEO

EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)
CSE Micro-site:

US OTC Markets:


EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online “digital healthcare” services for resolving common health problems. The current markets are weight-loss, high blood pressure, high blood glucose and heart arrhythmia.


Disclaimers – Forward Looking Statements

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on,, and This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.